JP2005200419A5 - - Google Patents

Download PDF

Info

Publication number
JP2005200419A5
JP2005200419A5 JP2005009439A JP2005009439A JP2005200419A5 JP 2005200419 A5 JP2005200419 A5 JP 2005200419A5 JP 2005009439 A JP2005009439 A JP 2005009439A JP 2005009439 A JP2005009439 A JP 2005009439A JP 2005200419 A5 JP2005200419 A5 JP 2005200419A5
Authority
JP
Japan
Prior art keywords
agonist
peroxisome proliferator
composition
responsive receptor
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2005009439A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005200419A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2005200419A publication Critical patent/JP2005200419A/ja
Publication of JP2005200419A5 publication Critical patent/JP2005200419A5/ja
Pending legal-status Critical Current

Links

JP2005009439A 2004-01-16 2005-01-17 癌治療法 Pending JP2005200419A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53723504P 2004-01-16 2004-01-16

Publications (2)

Publication Number Publication Date
JP2005200419A JP2005200419A (ja) 2005-07-28
JP2005200419A5 true JP2005200419A5 (enExample) 2008-02-28

Family

ID=34619679

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2005009439A Pending JP2005200419A (ja) 2004-01-16 2005-01-17 癌治療法

Country Status (4)

Country Link
US (2) US20050209292A1 (enExample)
EP (1) EP1555021A1 (enExample)
JP (1) JP2005200419A (enExample)
TW (1) TWI297606B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2222272B1 (en) * 2008-08-07 2012-11-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
US9150534B2 (en) 2012-02-28 2015-10-06 Northwestern University Prodrugs of fluorinated mevalonates to inhibit the mevalonate pathway of Streptococcus pneumoniae
CA2868311C (en) 2012-03-26 2021-06-22 Nippon Chemiphar Co., Ltd. Use of non-steroidal anti-inflammatory drugs (nsaids) and thiazolidinediones in the treatment of giant cell tumors occurring in a bone or soft tissue or of chondrosarcoma
WO2014054798A1 (ja) * 2012-10-04 2014-04-10 独立行政法人国立循環器病研究センター 悪性腫瘍転移抑制用医薬
CA2898113C (en) * 2013-01-14 2022-05-31 Health Clinics Limited Combination cancer therapeutics and uses thereof
JP6527822B2 (ja) 2013-09-25 2019-06-05 日本ケミファ株式会社 骨・軟部に発生する巨細胞性腫瘍、軟骨肉腫または骨肉腫の予防、治療または転移の予防のための薬剤、動脈塞栓術用局所注入剤、および、人工骨
EP3612177A4 (en) 2017-04-21 2021-01-13 Lunella Biotech, Inc. TARGETING HYPOXIC CARCINOUS STEM CELLS (SCC) USING DOXYCYCLINE: IMPLICATIONS FOR IMPROVING ANTI-ANGIOGENIC THERAPY
CA3060510A1 (en) 2017-04-21 2018-10-25 Lunella Biotech, Inc. Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs)
US12006553B2 (en) 2017-05-19 2024-06-11 Lunella Biotech, Inc. Companion diagnostics for mitochondrial inhibitors
JP6938682B2 (ja) 2017-05-19 2021-09-22 ルネラ・バイオテック・インコーポレーテッド アンチミトシン：癌幹細胞を根絶するためのミトコンドリア生合成の標的阻害薬
US20240058335A1 (en) * 2021-01-08 2024-02-22 Duke University Methods for treatment of cancer using abl inhibitors and drugs targeting the mevalonate pathway

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605930A (en) * 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
JP3651816B2 (ja) * 1995-07-03 2005-05-25 三共株式会社 動脈硬化症予防および治療剤
NZ286920A (en) * 1995-07-03 1997-06-24 Sankyo Co Use of combination of hmg-coa reductase inhibitors and of insulin sensitizers for the prevention/treatment of arteriosclerosis or xanthoma
DE69726182T2 (de) * 1996-12-11 2004-08-12 Dana-Farber Cancer Institute, Inc., Boston Methoden und pharmazeutische zusammenstellungen zur wachstumsverhinderung von tumorzellen enthaltend einen ppar-gamma agonisten und einen map kinase inhibitor
UA57081C2 (uk) * 1997-06-16 2003-06-16 Пфайзер Продактс Інк. Фармацевтична композиція для лікування раку або доброякісних проліферативних хвороб у ссавців, спосіб лікування, фармацевтична композиція для інгібування ненормального росту клітин у ссавців та спосіб інгібування
US6459003B1 (en) * 1999-04-01 2002-10-01 Esperion Therapeutics, Inc. Ether compounds
CA2399463A1 (en) * 2000-02-10 2001-08-16 Takeda Chemical Industries, Ltd. Combination drug
CA2415742A1 (en) * 2000-07-25 2002-01-31 Merck & Co., Inc. N-substituted indoles useful in the treatment of diabetes
JP2002128700A (ja) * 2000-08-16 2002-05-09 Sankyo Co Ltd 癌を予防及び治療するための医薬組成物
WO2003053974A1 (en) * 2001-12-21 2003-07-03 Dr. Reddy's Laboratories Ltd. Novel compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
US20040102360A1 (en) * 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy

Similar Documents

Publication Publication Date Title
EA200501586A1 (ru) Фармацевтические продукты
NO20045434L (no) En kombinasjon av en NMDA-antagonist og acetylkolinesteraseinhibitorer for behandlingen av Alzheimers sykdom
IL163931A (en) Derivatives of Tetrazycline Compounds Converted by Amino Methyl and Pharmaceutical Preparation Containing Them
JP2006526644A5 (enExample)
EE04990B1 (et) HMG reduktaasi inhibiitorit sisaldavad farmatseutilised kompositsioonid, nende kasutamine ja saamismeetod
EP2079462A4 (en) PHARMACEUTICAL COMPOSITIONS OF HDAC INHIBITORS AND CHELABLE METAL COMPOUNDS AND METALO HDAC HEMMER CHELATE COMPLEXES
MA31432B1 (fr) Metabolites de derives de (thio) carbamoyl-cyclohexane
WO2004073632A3 (en) Rapid absorption selective 5-ht agonist formulations
BRPI0412557A (pt) forma de dosagem farmacêutica de eventos cardiovasculares
DE602004020649D1 (de) Hdl-verstärkende kombinationstherapie-komplexe
BRPI0410727A (pt) composto, composição farmacêutica, e, uso de um composto
EP1619180A4 (en) CASR ANTAGONIST
NO20074109L (no) Intravenose formuleringer av PDE-5 inhibitorer
AU2003245313A1 (en) Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives (statins), novel combinations thereof as well as manufacturing of these pharmaceutical compositions
MA31706B1 (fr) Formulations galéniques de composés organiques
WO2008013833A3 (en) Orally dissolvable/disintegrable lyophilized dosage forms containing protected particles
JP2007512347A5 (enExample)
JP2006512361A5 (enExample)
RU2010109452A (ru) Способы и композиции, предназначенные для лечения раковых заболеваний
EA201401042A1 (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И КОМБИНИРОВАННОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ ИНГИБИТОРЫ HMG-CoA-РЕДУКТАЗЫ И ФОСФОДИЭСТЕРАЗЫ 4, И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ВОСПАЛИТЕЛЬНЫХ ЗАБОЛЕВАНИЙ ЛЕГКИХ
EA200801619A1 (ru) Способ улучшения фармакокинетики ингибиторов интегразы вич (варианты), набор и фармацевтическая композиция (варианты)
BRPI0411623A (pt) forma de dosagem farmacêutica ou dietética, esporopolenina, método para a formação de uma esporopolenina funcionalizada com amina primária ou um outro revestimento de exina, método para a formação de uma esporopolenina funcionalizada com poliamino ou um outro revestimento de exina de um esporo, método para a obtenção de uma esporopolenina funcionalizada com aminoácido ou um outro revestimento de exina de um esporo, esporopolenina funcionalizada ou um outro revestimento de exina de um esporo, forma de dosagem dietética ou flavorizante, método de preenchimento de revestimentos de exina de esporos, uso da forma de dosagem e método de aplicação oral de um ingrediente ativo
JP2009515927A5 (enExample)
WO2006091575A3 (en) Method of increasing drug oral bioavailability and compositions of less toxic orotate salts
RU2015111523A (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ОСНОВЕ КОМПОЗИТНЫХ КАПСУЛ, ВКЛЮЧАЮЩИХ ИРБЕСАРТАН И ИНГИБИТОР ГМГ-КоА РЕДУКТАЗЫ